PharmaCyte Biotech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.42
- Today's High:
- $2.5
- Open Price:
- $2.45
- 52W Low:
- $2.3
- 52W High:
- $3.23
- Prev. Close:
- $2.46
- Volume:
- 9737
Company Statistics
- Market Cap.:
- $21.59 million
- Book Value:
- 4.328
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -4.92%
- Return on Equity TTM:
- -5.31%
Company Profile
PharmaCyte Biotech Inc had its IPO on 2010-09-17 under the ticker symbol PMCB.
The company operates in the Healthcare sector and Biotechnology industry. PharmaCyte Biotech Inc has a staff strength of 2 employees.
Stock update
Shares of PharmaCyte Biotech Inc opened at $2.45 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.42 - $2.5, and closed at $2.42.
This is a -1.63% slip from the previous day's closing price.
A total volume of 9,737 shares were traded at the close of the day’s session.
In the last one week, shares of PharmaCyte Biotech Inc have slipped by -2.42%.
PharmaCyte Biotech Inc's Key Ratios
PharmaCyte Biotech Inc has a market cap of $21.59 million, indicating a price to book ratio of 0.6539 and a price to sales ratio of 0.
In the last 12-months PharmaCyte Biotech Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures PharmaCyte Biotech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PharmaCyte Biotech Inc’s operating margin was 0% while its return on assets stood at -4.92% with a return of equity of -5.31%.
In Q1.3333333333333, PharmaCyte Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
PharmaCyte Biotech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.23 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PharmaCyte Biotech Inc’s profitability.
PharmaCyte Biotech Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -11.2251. Its price to sales ratio in the trailing 12-months stood at 0.
PharmaCyte Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $73.28 million
- Total Liabilities
- $586581.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
PharmaCyte Biotech Inc ended 2024 with $73.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $73.28 million while shareholder equity stood at $72.69 million.
PharmaCyte Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $586581.00 in other current liabilities, 2160.00 in common stock, $-115958773.00 in retained earnings and $0 in goodwill. Its cash balance stood at $68.04 million and cash and short-term investments were $68.04 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
PharmaCyte Biotech Inc’s total current assets stands at $68.15 million while long-term investments were $1.57 million and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $128281.00 and inventory worth $0.
In 2024, PharmaCyte Biotech Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, PharmaCyte Biotech Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.42
- 52-Week High
- $3.23
- 52-Week Low
- $2.3
- Analyst Target Price
- $
PharmaCyte Biotech Inc stock is currently trading at $2.42 per share. It touched a 52-week high of $3.23 and a 52-week low of $3.23. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.61 and 200-day moving average was $2.87 The short ratio stood at 2.33 indicating a short percent outstanding of 0%.
Around 949.9% of the company’s stock are held by insiders while 2051.7% are held by institutions.
Frequently Asked Questions About PharmaCyte Biotech Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.